- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03311516
New Insulin Therapy by Multiwave Bolus (EVANEWFIT2)
Evaluation of Insulin Therapy by Multiwave Bolus Based on the Lipid and Protein Content in Addition to the Carbohydrates Content Compared to Insulin Therapy Based Only on the Carbohydrates Content in type1 Diabetes Treated by Insulin Pump
The aim of the study is to evaluate the effect of insulin therapy when the bolus dose of insulin is calculated on the basis of protein and fat content in food intake, in addition to that of carbohydrates in T1D patients treated by insulin pump. The study is planned to recruit 150 patients with type1 diabetes already practicing functional insulin therapy based on carbohydrate counting in meals. We will therefore study the effect on continuous glucose measured by subcutaneous sensor, of meal bolus adjustments by comparing two groups of T1D patients:
- Groupe A takes into account the lipid and protein content in addition to the carbohydrate content
- Group B takes into account the carbohydrate content only At randomization, all patients receive dietary and adjustment of bolus doses instructions according to the randomization group. They have to apply these instructions for 3 months. At the end of 3 months, the study groups will be under glucose monitoring during two weeks in the Outpatient Clinic but returns to the investigational site in hospital to download data from the continuous measurement of glucose. In addition, we propose a period of extension similar to that of the main period, namely 3 months of application of dietetic and adaptation of bolus doses instructions and 2 weeks of continuous measurement of glucose.
During each 2 weeks period will be assessed specific glucose parameters in the post-prandial period over 4hours (glycemic sensor values in the glucose range between 70-140 mg / dl, glycemic sensor values in the glucose range between 140 -180 mg /dl and > 180 mg /dl) after taking each meal during the 13 days of Glucose Continuous Measurement (GCM), average daily glucose per meal, average blood glucose over the 13-day period after each meal.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Siham BENZIRAR
- Phone Number: 0033383155028
- Email: s.benzirar@chru-nancy.fr
Study Contact Backup
- Name: JULIE LECOMTE-LEHMANN
- Phone Number: 0033383155278
- Email: ju.lecomte@chru-nancy.fr
Study Locations
-
-
-
Besançon, France
- Not yet recruiting
- Service d'Endocrinologie-Métabolisme et Diabétologie-Nutrition
-
Contact:
- Sophie BOROT
- Phone Number: 0033381668229
- Email: sophie.borot@univ-fcomte.fr
-
Principal Investigator:
- Sophie Borot
-
Dijon, France
- Recruiting
- Service d'endocrinologie et maladies métaboliques
-
Contact:
- Sabine RUDONI
- Phone Number: 0033380293453
- Email: sabine.rudoni@chu-dijon.fr
-
Principal Investigator:
- Sabine RUDONI
-
Nancy, France
- Recruiting
- Service d'Endocrinologie, Diabétologie et Nutrition
-
Contact:
- Siham BENZIRAR
- Phone Number: 0033383155028
- Email: s.benzirar@chru-nancy.fr
-
Principal Investigator:
- Bruno GUERCI
-
Reims, France
- Not yet recruiting
- Service Endocrinologie Diabète Nutrition
-
Contact:
- Sandrine PLISSON-RONEZ
- Phone Number: 0033326787159
- Email: splisson-ronez@chu-reims.fr
-
Principal Investigator:
- Céline LUKAS-CROISIER
-
Strasbourg, France
- Not yet recruiting
- Structure d'Endocrinologie, Diabète et Nutrition
-
Contact:
- Stéphanie Kocakaya
- Phone Number: 0033388116603
- Email: Stephanie.KOCAKAYA@chru-strasbourg.fr
-
Principal Investigator:
- Nathalie Jeandidier
-
Sub-Investigator:
- Laurent MEYER
-
Toulouse, France
- Not yet recruiting
- Service de diabétologie, maladies métaboliques et nutrition
-
Contact:
- Laurent CAZALS
- Phone Number: 0033561323361
- Email: cazals.l@chu-toulouse.fr
-
Principal Investigator:
- Hélène Hanaire
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Type 1 diabetic patient for more than one year, practicing functional insulin for at least 3 months but not more than 5 years
- Patient treated with external insulin pump (Medtronic or Omnipod pump)
- Patient performing intermittent blood glucose monitoring by the continuous interstitial glucose measurement system (Freestyle Libre) and who regularly wears this device with an achievement of at least 4 scans per day to obtain at least 90% of the possible values
- Patient with HbA1c ≤10.0% less than 3 months
- Patient with a willingness and ability to comply with study requirements and schedule of visits
- Patient who received complete information and signed informed consent
Exclusion Criteria:
- Patient with contraindication for rapid or ultra-rapid insulin analogues
- Patient for whom a change of insulin in the next 3 to 6 months is planned
- Women of childbearing age who do not have effective contraception
- Women who are pregnant or breast feeding or plan on becoming pregnant during the study
- Patient taking medication that interferes with interpretation of study results such as chronic corticosteroid therapy
- Patient with a chimio - or radiotherapy is in progress or is planned
- Patient abusing substances
- Patient who participated in another clinical study in the four weeks prior to inclusion
- Patient with or suspected of having any physical, psychological or cognitive disorders interfering with adherence to insulin therapy by pump, or compliance with dietary advice, or completion of the patient's diary
- Patient unable to comply with clinical guidelines, and unable to comply with 3-month follow-up
- Patient unable to understand information, to sign informed consent or to manage glycemic sensor
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group A
Group A = intervention group (new functional insulin therapy) who adjusts the insulin bolus according to a dose titration algorithm taking into account the lipid and protein content in addition to that of carbohydrates.
The functional insulin therapy is based on a Carbohydrate / Lipid / Protein count
|
the patient receives the dietary devices and the instructions for the adaptation of the insulin bolus dose according to a new FIT
Other Names:
|
Other: Group B
Group B=control group (functional insulin tehrapy) who adjusts the insulin bolus taking into account only the carbohydrate content.
The functional insulin therapy is based on a Carbohydrate count only.
|
the patient receives the dietary devices and the instructions for the adaptation of the insulin bolus dose according to FIT
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The ratio of normoglycemia values to total glucose values
Time Frame: at 14 weeks since the patient randomization
|
The ratio (expressed as a%) of the number of normoglycemia values over the total number of values collected over the 13-day period of the glucose monitoring
|
at 14 weeks since the patient randomization
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Continuous Glucose Measurement (CGM)
Time Frame: at 14 weeks and at 28 weeks since the patient randomization
|
Specific glycemic parameters in the post-prandial period over 4h (glycemic sensor values in the blood glucose range between 70-140 mg / dl, glycemic sensor values in the blood glucose area between 140 - 180 mg / dL and> 180 Mg / dl) after taking each meal during the 13 days of CGM, average daily glucose per meal, average blood glucose over the 13-day period after each meal
|
at 14 weeks and at 28 weeks since the patient randomization
|
HbA1c
Time Frame: at 14 weeks and at 28 weeks since the patient randomization
|
HbA1C dosage to assess glycemic control
|
at 14 weeks and at 28 weeks since the patient randomization
|
Sensor wearing time
Time Frame: 12 weeks, 14 weeks, 26 weeks and 28 weeks since the patient randomization
|
Sensor wearing time over the 3-month period and the 13-day CGM recording period
|
12 weeks, 14 weeks, 26 weeks and 28 weeks since the patient randomization
|
Number of sensor scans
Time Frame: 14 weeks and 28 weeks since the patient randomization
|
Number of sensor scans performed by the patient with corresponding time periods
|
14 weeks and 28 weeks since the patient randomization
|
Number of boluses performed
Time Frame: at 14 weeks and at 28 weeks since the patient randomization
|
Number of boluses performed over the 13-day period of the CGM
|
at 14 weeks and at 28 weeks since the patient randomization
|
Satisfaction of the patient with regard to his treatment
Time Frame: at inclusion, at 12 weeks and 26 weeks since randomisation
|
Patient satisfaction assessed by the DTSQs (status) and DTSQc (change)
|
at inclusion, at 12 weeks and 26 weeks since randomisation
|
Usability of the insulin pump
Time Frame: 14 weeks and 28 weeks since the patient randomization
|
Evaluate the use of pump functions by patient ex.
Bolus calculator, Temporary base rate
|
14 weeks and 28 weeks since the patient randomization
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2017-A02414-49
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type1diabetes
-
Silesian Centre for Heart DiseasesThe Jerzy Kukuczka Academy of Physical Education in KatowiceCompletedtype1diabetesPoland
-
Vastra Gotaland RegionActive, not recruitingType1diabetesSweden
-
Rabin Medical CenterThe Leona M. and Harry B. Helmsley Charitable Trust; DreaMed DiabetesRecruiting
-
University of Southern CaliforniaThe Leona M. and Harry B. Helmsley Charitable TrustCompletedType1diabetesUnited States
-
The Hospital for Sick ChildrenCanadian Institutes of Health Research (CIHR)Active, not recruiting
-
Aalborg University HospitalAalborg University; Steno Diabetes Center NordjyllandCompletedType1diabetes | Hemodialysis | Type2DiabetesDenmark
-
Vastra Gotaland RegionRecruitingType1diabetes | Psychology Functional BehaviorSweden
-
Radboud University Medical CenterUnknownType1diabetes | Hypoglycemia UnawarenessNetherlands
-
University of PennsylvaniaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National...Active, not recruitingHypoglycemia | Type1diabetes | Islet Cell Transplantation | Hypoglycemia UnawarenessUnited States
-
University of British ColumbiaJuvenile Diabetes Research Foundation; Brain CanadaNot yet recruiting
Clinical Trials on New functional insulin therapy
-
University Hospital, MontpellierCompleted
-
First Hospital of China Medical UniversityRecruitingEffects of Newly-created Individualized Upper Airway Muscle Functional Training on Patients With OSAObstructive Sleep Apnea | Muscle DisorderChina
-
University Hospital, AkershusUniversity of Oslo; Oslo University HospitalCompletedGastrointestinal Diseases | Gastrointestinal Neoplasms | Rectal Diseases | Rectal NeoplasmsNorway
-
University Hospital, AngersUnknownDiabetes Insulin DependentFrance
-
University Hospital, MontpellierTerminatedType 1 Diabetes | Basal-bolus Multiple-dily Insulin Injections | Insulin Pump (CSII)France
-
University GhentKU LeuvenCompletedCerebral Palsy, SpasticBelgium
-
KU LeuvenEuropean Social FundCompletedChronic Low Back PainBelgium
-
Riphah International UniversityCompletedCerebral PalsyPakistan
-
Riphah International UniversityCompleted
-
SanofiCompletedType 1 Diabetes MellitusUnited States, Canada, Czech Republic, Denmark, Estonia, Finland, Hungary, Japan, Latvia, Netherlands, Puerto Rico, Romania, Sweden